S095029
Phase 1Small molecule
S095029 is one of 73 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
3
Indications
3
Total Trials
3
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
S095029
SServier Bio-Innovation LLC
Phase 1
Immune Checkpoint Inhibitors
PPeking Union Medical College Hospital
Preclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer1 trial
Colorectal Cancer1 trial
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Active, not recruiting·
Institut de Recherches Internationales Servier·Phase 1·NCT05162755·41 enrolled
Institut de Recherches Internationales Servier·Phase 1·NCT05162755·41 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S095029. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SServier Bio-Innovation LLC